<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) has provided an announcement. GenFleet Therapeutics has issued a voluntary statement asserting that its Pan RAS inhibitor candidate GFH276 is based on fully independent and proprietary intellectual property, distancing itself from reported patent and trade secret disputes involving Revolution Medicines and a third party. The company says none of the entities or products mentioned in those disputes are related to GenFleet, and it has built a global patent portfolio for its Pan RAS program, including a core compound patent for GFH276 published in March 2025 with protection expected through 2044. GFH276 is described as an oral, novel small-molecule Pan RAS (ON) inhibitor that hijacks cyclophilin A to target active, GTP-bound RAS proteins across most wild-type and mutant subtypes, including common KRAS mutations such as G12C, G12D and G12V. Preclinical data indicate dose-dependent antitumor activity and tumor regression in multiple KRAS-mutant models, and the company positions GFH276 as having potential to outperform mainstream switch II pocket-based KRAS inhibitors, underscoring its strategic push to strengthen its competitive position in the oncology drug development landscape. More about Genfleet Therapeutics (Shanghai), Inc. Class H GenFleet Therapeutics (Shanghai) Inc. is a China-based biopharmaceutical company focused on developing innovative small-molecule therapies targeting cancer. Its pipeline includes next-generation RAS pathway inhibitors aimed at a broad range of wild-type and mutant tumor types in global oncology markets. Average Trading Volume: 2,225,832 Technical Sentiment Signal: Strong Buy Current Market Cap: HK$18.32B </div>

512290

516930

ARKG

516500

159992

159506

588130

GenFleet Therapeutics has announced that its Pan RAS inhibitor GFH276 is based on independent intellectual property, distancing itself from patent disputes involving Revolution Medicines. The company has a global patent portfolio for GFH276, which targets active RAS proteins and shows promise in preclinical trials for treating KRAS mutations. GenFleet aims to strengthen its position in oncology drug development with GFH276, which is expected to outperform existing KRAS inhibitors. The company is focused on innovative therapies for cancer and has a market cap of HK$18.32B.

Tip Ranks

Guotai CSI Bio-medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Ark Genomic Revolution ETF

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE STAR Biology and Medicine ETF

GENFLEET-B

Revolution Medicines

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

GenFleet Asserts Independent IP for Pan RAS Inhibitor GFH276 Amid Sector Dispute